Research Unit Analytical Pathology, Helmholtz Zentrum München, Ingolstaedter Landstrasse 1, 85764 Neuherberg (Germany).
Angew Chem Int Ed Engl. 2015 Mar 27;54(14):4279-83. doi: 10.1002/anie.201410555. Epub 2015 Feb 16.
Gadolinium(III)-based contrast agents improve the sensitivity and specificity of magnetic resonance imaging (MRI), especially when targeted contrast agents are applied. Because of nonlinear correlation between the contrast agent concentration in tissue and the MRI signal obtained in vivo, quantification of certain biological or pathophysiological processes by MRI remains a challenge. Up to now, no technology has been able to provide a spatially resolved quantification of MRI agents directly within the tissue, which would allow a more precise verification of in vivo imaging results. MALDI imaging mass spectrometry for spatially resolved in situ quantification of gadolinium(III) agents, in correlation to in vivo MRI, were evaluated. Enhanced kinetics of Gadofluorine M were determined dynamically over time in a mouse model of myocardial infarction. MALDI imaging was able to corroborate the in vivo imaging MRI signals and enabled in situ quantification of the gadolinium probe with high spatial resolution.
基于钆（III）的对比剂提高了磁共振成像（MRI）的灵敏度和特异性，尤其是在应用靶向对比剂时。由于组织中的对比剂浓度与体内获得的 MRI 信号之间存在非线性相关性，因此通过 MRI 定量某些生物学或病理生理学过程仍然是一个挑战。到目前为止，还没有技术能够在组织内直接提供 MRI 造影剂的空间分辨定量，这将允许更精确地验证体内成像结果。评估了用于与体内 MRI 相关的钆（III）造影剂的空间分辨原位定量的 MALDI 成像质谱法。在心肌梗死的小鼠模型中，随时间动态地确定了 Gadofluorine M 的增强动力学。MALDI 成像能够证实体内成像 MRI 信号，并能够以高空间分辨率对钆探针进行原位定量。
